Multiple myeloma
- Use multidrug induction built from proteasome/IMiD/antibody classes
- Transplant eligibility shapes initial strategy
- Autologous stem-cell transplant remains important for fit patients
- Maintenance therapy prolongs remission
- Relapse therapy follows prior exposure + cytogenetic risk
- Bone, kidney, infection + thrombosis supportive care is essential
Use at a glance
- Use multidrug induction built from proteasome/IMiD/antibody classes
Escalation / refractory disease
- Transplant eligibility shapes initial strategy
- Maintenance therapy prolongs remission
Later-line options
- Autologous stem-cell transplant remains important for fit patients
Monitoring / follow-up
- Relapse therapy follows prior exposure + cytogenetic risk
- Bone, kidney, infection + thrombosis supportive care is essential
Self-check
- What treatment approach is used in Multiple myeloma?
multidrug induction built from proteasome/IMiD/antibody classes.
Drugs used for this (2)
All clinical uses · Open the interactive console ↗
